CCL3L1Copy Number Is a Strong Genetic Determinant of HIV Seropositivity in Caucasian Intravenous Drug Users | Zendy

Kristi Huik | Zendy; Maarja Sadam | Zendy; Tõnis Karki | Zendy; Radko Avi | Zendy; Tõnu Krispin | Zendy; Piret Paap | Zendy; Kristi Rüütel | Zendy; Anneli Uusküla | Zendy; Ave Talu | Zendy; Katri AbelOllo | Zendy; Irja Lutsar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CCL3L1Copy Number Is a Strong Genetic Determinant of HIV Seropositivity in Caucasian Intravenous Drug Users

Author(s) -

Kristi Huik,

Maarja Sadam,

Tõnis Karki,

Radko Avi,

Tõnu Krispin,

Piret Paap,

Kristi Rüütel,

Anneli Uusküla,

Ave Talu,

Katri AbelOllo,

Irja Lutsar

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/650491

Subject(s) - hepatitis c virus , virology , immunology , medicine , hepatitis c , hepatitis b virus , odds ratio , hepatitis b , viral disease , biology , virus

A high copy number of CCL3L1, the most potent human immunodeficiency virus (HIV)-suppressive chemokine, associates with reduced HIV susceptibility. Whether CCL3L1 influences acquisition of multiple blood-borne infections (eg, hepatitis C virus [HCV], HIV, and hepatitis B virus [HBV] infections), which occur commonly among injection drug users (IDUs), is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research